Follows pregnant people with obesity who take Wegovy, and their babies
Observes safety outcomes in pregnant people with obesity who took semaglutide.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Princeton, United StatesSee the siteAlso in 2 other countries, 2 sites
- Trial code
- NCT05872022
- U1111-1273-4336
- Registry title
- A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
- Status
- Enrolling by invitation
- People taking part
- 728 people, planned
- Started
- 5 Jul 2023
- Expected to end
- 30 Dec 2032
- Type of study
- Observational, 2 groups
- Record updated
- 14 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who are or recently were pregnant and have obesity or overweight. One group took Wegovy in pregnancy; the other did not.
- Age
- 15 to 50 years
- Sex
- Women only
- Disease stage
- Obesity or overweight with at least one weight-related health condition
- Earlier treatment
- Wegovy group: took at least one dose of Wegovy during pregnancy. Comparison group: no Wegovy or other GLP-1 RA during pregnancy.
Main reasons for not taking part
- Mental incapacity, unwillingness or language barriers that prevent understanding or cooperation
- Comparison group: used Wegovy or another GLP-1 RA at any time during pregnancy
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Signed consent obtained before any study-related activities
- Female 15-50 years of age at the time of signing consent
- Currently or recently pregnant
- Resident of country included in the study
- Authorisation for her HCP(s) to provide data to the registry
- Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition
- Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception
Who cannot take part
- Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
- Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 50 years old?
Where in United States
Also in 2 other countries, 2 sites
- Princeton, New JerseyHospital not named in the registryEnrolling by invitation
About the trial
What the trial wants to find out
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.
The 2 groups in the trial
- Participants Exposed to Wegovy
Pregnant women who are exposed to Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition will be observed in this prospective observational study.
- Participants Unexposed to Wegovy or Other GLP-1 RAs
Pregnant women who have overweight with at least one weight-related comorbid condition or who have obesity at conception and who are not exposed to Wegovy or other GLP-1 RAs at any time during pregnancy but who may be exposed to other products for weight management will be observed in this prospective observational study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
- Plain-language title
- Follows pregnant people with obesity who take Wegovy, and their babiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05872022, who can take part
- Record updated
- 14 January 2026